Braveheart Bio grants 30,000 stock options to director

Braveheart Bio, Inc. director Jasper Bos received a grant of stock options covering 30,000 shares of common stock.

Rhea-AI Filing Summary

Braveheart Bio, Inc. director Jasper Bos received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $18.00 per share and expire on August 4, 2036. They vest in full on the earlier of August 5, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Bos holds 30,000 stock options directly.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider Bos Jasper

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Key Figures

Options Granted: 30,000 options Exercise Price: $18.00 per share Expiration Date: August 4, 2036 +3 more

6 metrics

Options Granted 30,000 options Stock Option (Right to Buy) grant to director Jasper Bos on 2026-08-05

Exercise Price $18.00 per share Exercise price for the 30,000 stock options granted

Expiration Date August 4, 2036 Expiration of stock options granted to Jasper Bos

Underlying Shares 30,000 shares Common stock underlying the granted stock options

Holdings After Grant 30,000 options Total stock options held directly by Jasper Bos after the reported grant

Vesting Date August 5, 2027 Latest possible vesting date, or earlier on next annual meeting of stockholders

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 18.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares underlying the stock option will vest in full upon the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Jasper Bos report on Braveheart Bio (BRVE)?

Jasper Bos reported a grant of stock options for 30,000 shares of Braveheart Bio common stock, received as a compensation-related award rather than a market purchase or sale.

What is the exercise price of the stock options granted to Jasper Bos at BRVE?

The stock options granted to Jasper Bos have an exercise price of $18.00 per share, meaning he can purchase Braveheart Bio common stock at that price once the options vest.

When do Jasper Bos’s Braveheart Bio (BRVE) options vest?

The options will vest in full on the earlier of August 5, 2027 or the date of Braveheart Bio’s next annual meeting of stockholders, contingent on his continued service.

When do the Braveheart Bio (BRVE) options granted to Jasper Bos expire?

The stock options granted to Jasper Bos expire on August 4, 2036. After this date, any unexercised options will lapse and can no longer be used to purchase shares.

How many Braveheart Bio (BRVE) stock options does Jasper Bos hold after this grant?

After this grant, Jasper Bos holds 30,000 stock options directly. Each option is exercisable for one share of Braveheart Bio common stock, subject to the vesting conditions.

Is Jasper Bos’s Braveheart Bio (BRVE) option grant under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that this compensation-related stock option grant was made pursuant to a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 08:04 PM Accepted by SEC EDGAR 08/07/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bos Jasper

(Last) (First) (Middle)

C/O BRAVEHEART BIO, INC.

ONE LETTERMAN DR., BLDG. A, SUITE A4-300

(Street)

SAN FRANCISCO CALIFORNIA 94129

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Braveheart Bio, Inc. [ BRVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18	08/05/2026		A		30,000		(1)	08/04/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Remarks:

	/s/ James Paul Rickey, Attorney-in-Fact	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)